• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Elevance Health Inc. (Amendment)

    2/9/23 11:16:45 AM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    SC 13G/A 1 tv0800-elevancehealthinc.htm SCHEDULE 13G/A elevancehealthinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  Elevance Health Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  036752103

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  036752103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    344,756

    7.  SOLE DISPOSITIVE POWER

    20,480,638

    8.  SHARED DISPOSITIVE POWER

    992,806

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    21,473,444

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.99%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Elevance Health Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    220 Virginia Avenue
    Indianapolis, IN 46204

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    036752103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    5/20/2026$498.00Hold → Buy
    Deutsche Bank
    4/29/2026$435.00Neutral → Buy
    BofA Securities
    4/8/2026$345.00In-line
    Evercore ISI
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    More analyst ratings

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

    Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym

    6/25/26 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00

    5/20/26 8:03:29 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00

    4/29/26 8:00:15 AM ET
    $ELV
    Medical Specialities
    Health Care

    Evercore ISI initiated coverage on Elevance Health with a new price target

    Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00

    4/8/26 8:36:16 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    6/15/26 4:10:45 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 11:27:18 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 6:01:33 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:58:21 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance

    1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in

    4/22/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care